Bob Oliver MBA

Bob managed a $6B P&L at Otsuka while managing a diverse and growing product portfolio across the cardio-renal, neuroscience, oncology, and medical device markets. Having compiled more than 25 years of experience in the pharmaceutical industry, across commercial and general management roles for premium companies within industry he was instrumental in building ABILIFY, Abilify Maintena, SAMSCA, SPRYCEL and Rexulti. As Vice President and Global Business Manager for Oncology at Wyeth, he led the global launch of Torisel for RCC and later assumed responsibility for U.S. Commercial Operations.
Bob began his career in pharmaceuticals with Johnson & Johnson where he held positions of increasing responsibility. During his tenure at Otsuka Bob held senior level executive roles including President & COO for North America and most recently Bob was in the role of President & CEO of Otsuka America Pharmaceuticals, Inc. He currently maintains the position of Board Chairman for Otsuka Canada. Bob is also Executive Advisor and a member of the Board of Directors for Hyalo Technologies; as well as Board Member of Neurotez both Biotech start ups. Previously Bob served on the board of Immunomedics a publicly traded company focused on Oncology.